Barnes Group Inc. - B STOCK NEWS

BioArctic AB, listed as BIOA B on Nasdaq Stockholm, will release its first quarter report for January - March 2023 on April 27, 2023, at 08:00 a.m. CET.

The company will host an audiocast with teleconference at 09:30 CET on the same day, featuring CEO Gunilla Osswald and CFO Jan Mattsson. This session will include a presentation of the financial results followed by a Q&A segment.

Investors and analysts can participate via a webcast or teleconference by registering through the provided links. The presentation will be subsequently available on BioArctic's corporate website.

Hexagon's Manufacturing Intelligence division introduced the PRESTO automated robotic inspection cell on April 18, 2023, aimed at enhancing quality inspection efficiency for manufacturers, particularly in the automotive sector. PRESTO reduces inspection times significantly, allowing for real-time data processing and minimal setup, thus accommodating the shift towards electric vehicles (EVs). It integrates advanced 3D scanning and positioning technologies, connecting inspection to the manufacturing ecosystem and optimizing product lifecycles. This user-friendly solution requires no specialized robotics expertise, addressing the industry's labor shortages. By enabling faster adaptation for various parts, PRESTO aims to streamline workflows and reduce time to market, catering to manufacturers facing dynamic market demands.

ETQ, part of Hexagon, announced key milestones for Q1 2023, including the appointment of Vick Vaishnavi as CEO and an expanded global customer base. The company attracted new clients from sectors such as life sciences, aerospace, and packaging, while existing customers increased their use of ETQ Reliance. Enhancements were made to the ETQ Reliance Quality Management System (QMS), improving capabilities for cloud-native solutions. ETQ received industry recognition from Frost & Sullivan, highlighting its consistent growth and innovation in the QMS space. The progress reinforces ETQ's commitment to providing value in quality management and compliance.

MediaKind and Net Insight have partnered to develop a cloud-first IP video distribution system, enhancing broadcast technologies. This collaboration integrates Net Insight’s Nimbra Edge with MediaKind’s RX1 and CE1 devices, providing an end-to-end solution for broadcasters and video distributors. The system supports high-quality live content distribution with low latency and robust security features like end-to-end encryption. Moreover, MediaKind's Aquila Live platform offers compatibility with multiple broadcast protocols and ingest formats, ensuring flexibility for customers. This partnership aims to simplify live video workflows while reinforcing market positions for both companies. The solution will be showcased at the NAB Show from April 16th to 19th, 2023.

BioArctic AB (NASDAQ Stockholm: BIOA B) announced that its partner Eisai published a study in Neurology and Therapy detailing long-term outcomes of lecanemab, an antibody for Alzheimer's disease. The study indicates that lecanemab can delay progression of mild cognitive impairment and early Alzheimer's by 2-3 years compared to standard care, improving patients' quality of life. This analysis includes data from the Phase 3 Clarity AD trial, contrasting lecanemab treatment with standard care. Lecanemab gained accelerated FDA approval in January 2023, and Eisai is pursuing further regulatory approvals globally, including in the U.S., Japan, and Europe.

BioArctic AB (NASDAQ Stockholm: BIOA B) presented significant findings on lecanemab, an antibody for Alzheimer's disease, at the 2023 AD/PD conference. The Phase 3 Clarity AD study involving 1,795 participants confirmed the efficacy of lecanemab, achieving its primary and all key secondary endpoints with strong statistical significance. Presentations highlighted the unique mechanism of action of lecanemab, ARIA incidences, and quality of life improvements for patients and caregivers. BioArctic, partnered with Eisai, is preparing for the joint commercialization of lecanemab in the Nordic region, where BioArctic holds the rights to market the drug.

On March 31, 2023, BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner, Eisai, published detailed analyses from the phase 2b clinical study of lecanemab for treating mild cognitive impairment and early Alzheimer's disease. The multicenter study enrolled 856 patients, showing a consistent reduction in clinical decline over 18 months and demonstrating the potential for disease modification. Lecanemab exhibited a low incidence of amyloid-related imaging abnormalities (ARIA), with manageable side effects. BioArctic retains commercialization rights for lecanemab in the Nordic region, and both companies are preparing for joint commercialization.

BioArctic's partner, Eisai, has published new research on the societal value of the anti-amyloid-beta antibody, lecanemab (LEQEMBI™), in Alzheimer's disease. This study utilized data from the Phase 3 Clarity AD trial, revealing a gain of 0.61 quality-adjusted life-years (QALYs) from a healthcare payer perspective and a reduction in costs by $6,263 per person. For the societal perspective, the QALY gain is 0.64 and costs decrease by $7,451. Lecanemab, which received accelerated FDA approval on January 18, 2023, could significantly improve quality of life and lessen the economic burden of Alzheimer's disease.

Barnes Group Inc. (NYSE: B) will release its first quarter 2023 financial results on April 27, 2023, before market opens. The company will host a conference call at 8:30 a.m. (ET) to discuss results and future outlook, accessible via a live audio webcast on their website. A recorded playback will be available from 12:00 p.m. (ET) on April 27 until 11:59 p.m. (ET) on May 4, 2023. Barnes specializes in advanced technology solutions across various industries, including medical and aerospace, enhancing production and sustainability through integrated hardware and software.